欢迎来到天天文库
浏览记录
ID:55315197
大小:227.73 KB
页数:3页
时间:2020-05-14
《肝硬化患者临床检验血清学指标检测分析.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、中国医院统计2013年4月第20卷第2期·97·肝硬化患者临床检验血清学指标检测分析章丽娟【摘要】目的探讨肝硬化患者临床检验血清学指标,评价和判断在诊断中的应用价值,为临床肝硬化诊断提供依据。方法我院2010年1月至2012年12月的肝硬化患者120例,其中肝硬化代偿期和失代偿期患者各60例,对照组60例,对其相关血清学指标进行统计分析。结果失代偿期肝硬化和代偿期肝硬化TBIL和AIJT分别为67.1±12.4txmolfL、142.5+13.4U/L和42.8±8.1~mol/L、78.6+-12.7U/L,差异有显著性(P
2、3、1.3#g/L,均高于代偿期肝硬化和对照组,且代偿期肝硬化组高于对照组,差异有显著性(P<0.05);失代偿期肝硬化HA和PcⅢ为210.3_+16.31zg/L和169.7-+17.4g/L,均高于对照组,差异有显著性(P<0.05)。结论几项指标联合检测对于肝硬化临床诊断和预后判断有重要的参考价值。【关键词】肝硬化肝功能临床检验肝纤维化SerologicalindicatoranalysisofpatientswithcirrhosisonclinicalinspectionZhangL~iuan.Thesecondpeo4、pleshospitalofLiShui,clinicallaboratory,Lishui323000,China【Abstract】ObjectiveToexploretheserologicalindicatoranalysisofpatientswithcirrhosisonclinicalinspectionfore—valuationandjudgmentofthecirhosis,andtoprovidethebasisfordiagnosisoflivercirrhosis.Methods120patients5、withcir—rhosiswereselectedfromJanuary2010toDecember2012inourhospita1.Eachofthe60patientswithlivercirhosiswereincompensatorystageanddeeompensatorystageandthecontrolgrouphad60patients.Theirserologicalindicatorswerestatisticallyanalyzed.ResultsTBILandAofdecompensatecir6、hosisandlivercirrhosiswere67.1±12.4#mol/L.142.5_+13.4U/Land42.8±8.1/zmol/L,78.6±12.7U/L.Thedifferencewasstatisticallysignificant(P<0.05),andbothgroupswerehigherthanthecontrolgroup(P<0.05).Albofthedecompensatecirhosiswas274±5.9g/L,lowerthanthecontrolgroupandlivercirh7、o—sisgroup(P<0.05).FordecompensatecirrhosisandlivercirrhosisPA,ChE,andtheADAwere0.14_+0.08mg/L,2043.38±901.26U/L,15.28±4.92U/Land0.20_+0.14mg/L,3625.46_+983.08U/L,33.85±5.41U/Lrespectively.Thedifferencewasstatisticallysignificant(P<0.05).Comparedwiththecontrolgroup,8、thedifferencewasstatisticallysignificant(P<0.05).IV—CandLNofdecompensatecirrhosiswere96.5±13.7g/Land204.6±21.3g/L,higherthanthosewithliver
3、1.3#g/L,均高于代偿期肝硬化和对照组,且代偿期肝硬化组高于对照组,差异有显著性(P<0.05);失代偿期肝硬化HA和PcⅢ为210.3_+16.31zg/L和169.7-+17.4g/L,均高于对照组,差异有显著性(P<0.05)。结论几项指标联合检测对于肝硬化临床诊断和预后判断有重要的参考价值。【关键词】肝硬化肝功能临床检验肝纤维化SerologicalindicatoranalysisofpatientswithcirrhosisonclinicalinspectionZhangL~iuan.Thesecondpeo
4、pleshospitalofLiShui,clinicallaboratory,Lishui323000,China【Abstract】ObjectiveToexploretheserologicalindicatoranalysisofpatientswithcirrhosisonclinicalinspectionfore—valuationandjudgmentofthecirhosis,andtoprovidethebasisfordiagnosisoflivercirrhosis.Methods120patients
5、withcir—rhosiswereselectedfromJanuary2010toDecember2012inourhospita1.Eachofthe60patientswithlivercirhosiswereincompensatorystageanddeeompensatorystageandthecontrolgrouphad60patients.Theirserologicalindicatorswerestatisticallyanalyzed.ResultsTBILandAofdecompensatecir
6、hosisandlivercirrhosiswere67.1±12.4#mol/L.142.5_+13.4U/Land42.8±8.1/zmol/L,78.6±12.7U/L.Thedifferencewasstatisticallysignificant(P<0.05),andbothgroupswerehigherthanthecontrolgroup(P<0.05).Albofthedecompensatecirhosiswas274±5.9g/L,lowerthanthecontrolgroupandlivercirh
7、o—sisgroup(P<0.05).FordecompensatecirrhosisandlivercirrhosisPA,ChE,andtheADAwere0.14_+0.08mg/L,2043.38±901.26U/L,15.28±4.92U/Land0.20_+0.14mg/L,3625.46_+983.08U/L,33.85±5.41U/Lrespectively.Thedifferencewasstatisticallysignificant(P<0.05).Comparedwiththecontrolgroup,
8、thedifferencewasstatisticallysignificant(P<0.05).IV—CandLNofdecompensatecirrhosiswere96.5±13.7g/Land204.6±21.3g/L,higherthanthosewithliver
此文档下载收益归作者所有